Emergent BioSolutions Reports Q3 2026 Financial Results and Leadership Changes

Emergent BioSolutions Inc. reported its financial results for the third quarter ended September 30, 2026, noting total revenues of $110.0 million. This figure represents a 52% decrease compared to the same period in the prior year, which totaled $231.1 million. The company reported a net loss of $32.7 million for the quarter, resulting in a net loss margin of 30%. Adjusted net loss for the period was $18.7 million, and adjusted EBITDA was a loss of $4.6 million.

Revenue performance varied by product segment. Naloxone product revenues decreased by 42% year-over-year to $43.5 million, primarily due to lower sales of over-the-counter NARCAN nasal spray driven by an unfavorable price-volume mix in U.S. public interest channels. Conversely, Anthrax MCM revenues increased by $23.7 million year-over-year to $25.1 million, attributed to higher sales of CYFENDUS anthrax vaccine due to timing. Smallpox MCM revenues decreased by 68% to $26.7 million, driven by lower sales of ACAM2000 and CNJ-016 (VIGIV) due to timing, partially offset by higher sales of TEMBEXA.

Year-to-date 2026 results showed total revenues of $500.4 million, a 16% decrease from the prior year. The company reported a year-to-date net loss of $206.1 million. Adjusted net income for the year was $24.1 million. Gross margin for the third quarter was 14%, while adjusted gross margin was 28%.

In other business updates, Emergent announced that Executive Vice President and Chief Financial Officer Richard S. Lindahl will retire effective December 31, 2026, serving as a part-time advisor through March 31, 2027. Frank Vargo, Vice President of Treasurer, will serve as interim CFO beginning January 1, 2027. The company also completed a repurchase of $75 million in aggregate principal amount of Senior Unsecured Notes and implemented restructuring efforts aimed at improving the cost structure and aligning resourcing to current needs. Additionally, the company was awarded a contract modification valued at approximately $24 million for CYFENDUS and a 'Standing Offer' for NARCAN nasal spray from the Government of Canada.